Patients with ROS1 rearrangement‐positive non‐small‐cell lung cancer benefit from pemetrexed‐based chemotherapy

ROS1 gene‐rearrangement in non‐small‐cell lung cancer (NSCLC) patients has recently been identified as a driver gene and benefited from crizotinib treatment. However, no data are available for ROS1‐positive NSCLC about chemotherapeutic options and prognostic data. We investigated pemetrexed‐based tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Zhengbo, Su, Haiyan, Zhang, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083720/
https://www.ncbi.nlm.nih.gov/pubmed/27544536
http://dx.doi.org/10.1002/cam4.809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083720/
https://www.ncbi.nlm.nih.gov/pubmed/27544536
http://dx.doi.org/10.1002/cam4.809

Ejemplares similares